These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 38888931)
1. Elucidating the Role of Human ALAS2 C-terminal Mutations Resulting in Loss of Function and Disease. Taylor JL; Ayres-Galhardo PH; Brown BL Biochemistry; 2024 Jul; 63(13):1636-1646. PubMed ID: 38888931 [TBL] [Abstract][Full Text] [Related]
2. Anti-Correlation between the Dynamics of the Active Site Loop and C-Terminal Tail in Relation to the Homodimer Asymmetry of the Mouse Erythroid 5-Aminolevulinate Synthase. Na I; Catena D; Kong MJ; Ferreira GC; Uversky VN Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958424 [TBL] [Abstract][Full Text] [Related]
3. Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients. Fratz-Berilla EJ; Breydo L; Gouya L; Puy H; Uversky VN; Ferreira GC Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):428-439. PubMed ID: 27838491 [TBL] [Abstract][Full Text] [Related]
5. Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias. Peoc'h K; Nicolas G; Schmitt C; Mirmiran A; Daher R; Lefebvre T; Gouya L; Karim Z; Puy H Mol Genet Metab; 2019 Nov; 128(3):190-197. PubMed ID: 30737140 [TBL] [Abstract][Full Text] [Related]
6. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2). Bishop DF; Tchaikovskii V; Hoffbrand AV; Fraser ME; Margolis S J Biol Chem; 2012 Aug; 287(34):28943-55. PubMed ID: 22740690 [TBL] [Abstract][Full Text] [Related]
7. Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia. Fujiwara T; Okamoto K; Niikuni R; Takahashi K; Okitsu Y; Fukuhara N; Onishi Y; Ishizawa K; Ichinohasama R; Nakamura Y; Nakajima M; Tanaka T; Harigae H Biochem Biophys Res Commun; 2014 Nov; 454(1):102-8. PubMed ID: 25450364 [TBL] [Abstract][Full Text] [Related]
8. Structural basis for dysregulation of aminolevulinic acid synthase in human disease. Taylor JL; Brown BL J Biol Chem; 2022 Mar; 298(3):101643. PubMed ID: 35093382 [TBL] [Abstract][Full Text] [Related]
9. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. To-Figueras J; Ducamp S; Clayton J; Badenas C; Delaby C; Ged C; Lyoumi S; Gouya L; de Verneuil H; Beaumont C; Ferreira GC; Deybach JC; Herrero C; Puy H Blood; 2011 Aug; 118(6):1443-51. PubMed ID: 21653323 [TBL] [Abstract][Full Text] [Related]
13. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. Astner I; Schulze JO; van den Heuvel J; Jahn D; Schubert WD; Heinz DW EMBO J; 2005 Sep; 24(18):3166-77. PubMed ID: 16121195 [TBL] [Abstract][Full Text] [Related]
14. GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia. Daher R; Mansouri A; Martelli A; Bayart S; Manceau H; Callebaut I; Moulouel B; Gouya L; Puy H; Kannengiesser C; Karim Z Mol Genet Metab; 2019 Nov; 128(3):342-351. PubMed ID: 30660387 [TBL] [Abstract][Full Text] [Related]
15. Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). Ducamp S; Schneider-Yin X; de Rooij F; Clayton J; Fratz EJ; Rudd A; Ostapowicz G; Varigos G; Lefebvre T; Deybach JC; Gouya L; Wilson P; Ferreira GC; Minder EI; Puy H Hum Mol Genet; 2013 Apr; 22(7):1280-8. PubMed ID: 23263862 [TBL] [Abstract][Full Text] [Related]
16. 5-aminolevulinate synthase: catalysis of the first step of heme biosynthesis. Hunter GA; Ferreira GC Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):102-10. PubMed ID: 19268008 [TBL] [Abstract][Full Text] [Related]